Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.71 USD | -0.78% | +1.52% | -12.86% |
05-10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
05-10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.86% | 91.34B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $69 From $81, Maintains Buy Rating